AAAAAA

   
Results: 1-7 |
Results: 7
Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: Comparison with single and multiple daily doses of Filgrastim
Authors: van der Auwera, P Platzer, E Xu, ZX Schulz, R Feugeas, O Capdeville, R Edwards, DJ
Citation: P. Van Der Auwera et al., Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: Comparison with single and multiple daily doses of Filgrastim, AM J HEMAT, 66(4), 2001, pp. 245-251
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinasein chronic myeloid leukemia.
Authors: Druker, BJ Talpaz, M Resta, DJ Peng, B Buchdunger, E Ford, JM Lydon, NB Kantarjian, H Capdeville, R Ohno-Jones, S Sawyers, CL
Citation: Bj. Druker et al., Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinasein chronic myeloid leukemia., N ENG J MED, 344(14), 2001, pp. 1031-1037
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia withthe philadelphia chromosome.
Authors: Druker, BJ Sawyers, CL Kantarjian, H Resta, DJ Reese, SF Ford, JM Capdeville, R Talpaz, M
Citation: Bj. Druker et al., Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia withthe philadelphia chromosome., N ENG J MED, 344(14), 2001, pp. 1038-1042
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.
Authors: Joensuu, H Roberts, PJ Sarlomo-Rikala, M Andersson, LC Tervahartiala, P Tuveson, D Silberman, SL Capdeville, R Dimitrijevic, S Druker, B Demetri, GD
Citation: H. Joensuu et al., Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor., N ENG J MED, 344(14), 2001, pp. 1052-1056
Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors
Authors: Eskens, FALM Greim, GA van Zuylen, C Wolff, I Denis, LJ Planting, AST Muskiet, FA Wanders, J Barbet, NC Choi, L Capdeville, R Verweij, J Hanauske, AR Bruntsch, U
Citation: Falm. Eskens et al., Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors, CLIN CANC R, 6(5), 2000, pp. 1736-1743
Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486Ain phase I studies in patients with advanced cancers
Authors: Zhou, HH Choi, L Lau, H Bruntsch, U De Vries, EEGE Eckhardt, G Van Oosterom, AT Verweij, J Schran, H Barbet, N Linnartz, R Capdeville, R
Citation: Hh. Zhou et al., Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486Ain phase I studies in patients with advanced cancers, J CLIN PHAR, 40(3), 2000, pp. 275-283
A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours
Authors: Paridaens, R Uges, DRA Barbet, N Choi, L Seeghers, M van der Graaf, WTA Groen, HJM Dumez, H Van Buuren, I Muskiet, F Capdeville, R van Oosterom, AT de Vries, EGE
Citation: R. Paridaens et al., A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours, BR J CANC, 83(5), 2000, pp. 594-601
Risultati: 1-7 |